动物**测量仪，非常适合对大鼠小鼠等动物的皮下**进行快速测量、分析，精确测量动物**并对**信息存档与跟踪。

主要技术参数： 

· 测量范围：0-25mm**尺寸：20*20*20mm
· 3D测量精确度：<0.3mm
· 图像捕捉时间：0.1s
· 接口：USB 2.0
· 相机：1600*1200 像素（2MP）
· 工作距离：50mm

动物**测量分析仪的主要特点： 
· 手持式成像装置，实现立体成像；
· 适合测量不同尺寸的**；
· 方便使用：触屏式电脑，操作方便；
· 内置软件，自动计算**尺寸，跟踪整个实验进展。 
  

· 快速，高效，保证了高通量和可靠测量；
· 全自动测量跟踪系统；
· 实时数据分析与处理。 

部分用户： 

Hunter College, CUNY

Vanderbilt University Medical Center

Hainan Medical University

Howard Hughes Medical Institute

Memorial Sloan Kettering Cancer Center

Cancer Center Amsterdam

GlaxoSmithKline

Imec

K.U.Leuven

Neuro-Electronics Research Flanders

Pepric

PharmaVize

reMYND

University Ghent

SEPS Pharma

Vlaams Instituut voor Biotechnologie

University Antwerp

ThromboGenics

Janssen Pharmaceutica

City University of Hong Kong

参考文献：

1.Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408-412. doi:10.1038/s41586-019-1318-9.
2.Zhang Z, Zhou C, Li X, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. 2020;37(4):584-598.e11. doi:10.1016/j.ccell.2020.03.001.
3.Santich BH, Park JA, Tran H, et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med. 2020;12(534):eaax1315. doi:10.1126/scitranslmed.aax1315.
4.Park JA, Xu H, Cheung, I, et al. Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy. Cancer Res. 2018;78(19),B38.doi:10.1158/1538-7445.PEDCA17-B38.
5.Wu CF, Wu CY, Lin CF, et al. The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. Biomed Pharmacother. 2022;151:113128. doi:10.1016/j.biopha.2022.113128.
6.Wang L, Hoseini SS, Xu H, et al. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. Cancer Immunol Res. 2019;7(12):2013-2024. doi:10.1158/2326-6066.CIR-19-0121.
7.Grochowska A, Statkiewicz M, Kulecka M, et al. Evidence supporting the oncogenic role of BAZ1B in colorectal cancer. Am J Cancer Res. 2022;12(10):4751-4763. 
8.Hoseini SS, Vadlamudi M, Espinosa-Cotton M, et al. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021;9(5):e002509. doi:10.1136/jitc-.
9.Beguin E, Gray MD, Logan KA, et al. Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device. J Control Release. 2020;317:23-33. doi:10.1016/j.jconrel.2019.11.013.
10.Mao N, Gao D, Hu W, et al. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Mol Cancer Ther. 2019;18(9):1577-1586. doi:10.1158/1535-7163.MCT-18-1386.
11.Wu Z, Guo HF, Xu H, et al. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Mol Cancer Ther. 2018;17(10):2164-2175. doi:10.1158/1535-7163.MCT-18-0026.
12.Poty S, Mandleywala K, O'Neill E, et al. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 2020;10(13):5802-5814. doi:10.7150/thno.44772.
13.Hoseini SS, Guo H, Wu Z, et al. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv. 2018;2(11):1250-1258. doi:10.1182/bloodadvances.2017014373.
14.Zhang Z, Karthaus WR, Lee YS, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020;38(2):279-296.e9. doi:10.1016/j.ccell.2020.06.005.
15.Poty S, Carter LM, Mandleywala K, et al. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019;25(2):868-880. doi:10.1158/1078-0432.CCR-18-1650.